SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Abroad (travel likely)RecruitingPHASE1

Conditions

Neuroendocrine Carcinoma · Neuroendocrine Tumors

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Miami, Miami, Florida, United States
Contact: Study coordinator (Peter Hosein, MD) · PHosein@med.miami.edu · 305-243-3462
Contact: Study coordinator (Nailet Real Bestard, MS) · nxr518@med.miami.edu · +1 (305) 2438173
Contact: Principal Investigator (Peter Hosein, MD)

Study leads

Peter Hosein, MD
Principal Investigator
University of Miami

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine Tumors · Well-Differentiated Neuroendocrine Carcinoma · High Grade Neuroendocrine Carcinoma, Any Site

Abroad (travel likely)RecruitingPHASE2

San Francisco, United States

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)

Neuroendocrine Tumors · Neuroendocrine Neoplasm · Neuroendocrine Tumor Grade 1

Abroad (travel likely)Recruiting

Rome, Italy

Clinical Application of the J-PET Scanner Prototype

Prostate Cancer · Prostatic Hyperplasia · Prostatic Neoplasms

Abroad (travel likely)Recruiting

Krakow, Poland

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Anchorage, United States